Ovid’s playful poetry made him a favorite among Rome’s elite, but angered Emperor Augustus. Just as he was producing his finest work, Ovid (43 BC – 17 AD) was exiled to the darkest corner of ...

In a report released today, Sarah Schram from William Blair maintained a Buy rating on Ovid Therapeutics (OVID – Research Report). The company’s shares closed yesterday at $0.49. Effectively ...

Stelios Papadopolous, Ph.D., a pioneering leader in biotech, appointed to Board of Directors; two industry veterans joined management team as Ovid prepares to take OV329 into patient trials and ...